Surgery Timing and TREM2 Shape CAR-T Activity in Glioblastoma Models

A peer-reviewed study finds that glioblastoma surgery drives TREM2-positive myeloid remodeling that impairs CAR-T function, and that preoperative CAR-T dosing outperformed postoperative dosing in mouse models.

Company: University of Geneva / Geneva University Hospitals · Event Type: Peer-Reviewed Publication · Modality: CAR-T Cell Therapy · Target: TREM2 (myeloid checkpoint) · Disease Area: Glioblastoma Summary A July 31, 2026 peer-reviewed publication reports that glioblastoma resection rapidly remodels the local myeloid compartment, with…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Pfizer – SF R&D Site Closure
Tempus Acquires Personalis for $1.5 Billion
Waypoint Bio – China IIT CAR-T Strategy
J&J Completes Firefly Bio Acquisition